Summary
54.55 -0.27(-0.49%)07/01/2024
LivaNova PLC (LIVN)
LivaNova PLC (LIVN)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.44 | 0.23 | -9.43 | -1.11 | 7.93 | 7.02 | -24.51 | -21.99 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 54.55 | |
| Open | 54.88 | |
| High | 55.54 | |
| Low | 54.34 | |
| Volume | 290,991 | |
| Change | -0.24 | |
| Change % | -0.44 | |
| Avg Volume (20 Days) | 500,969 | |
| Volume/Avg Volume (20 Days) Ratio | 0.58 | |
| 52 Week Range | 42.82 - 64.48 | |
| Price vs 52 Week High | -15.40% | |
| Price vs 52 Week Low | 27.39% | |
| Range | -0.60 | |
| Gap Up/Down | -0.44 | |
Fundamentals | ||
| Market Capitalization (Mln) | 2,950 | |
| EBIDTA | 64,337,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 5.0239 | |
| WallStreet Target Price | 106.00 | |
| Book Value | 24.6610 | |
| Earnings Per Share | -8.2330 | |
| EPS Estimate Current Quarter | 0.4400 | |
| EPS Estimate Next Quarter | 0.5800 | |
| EPS Estimate Current Year | 2.0700 | |
| EPS Estimate Next Year | 2.5800 | |
| Diluted EPS (TTM) | -8.2330 | |
| Revenues | ||
| Profit Marging | -0.3934 | |
| Operating Marging (TTM) | 0.0097 | |
| Return on asset (TTM) | 0.0027 | |
| Return on equity (TTM) | -0.3053 | |
| Revenue TTM | 1,034,856,000 | |
| Revenue per share TTM | 20.9200 | |
| Quarterly Revenue Growth (YOY) | 0.0550 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 605,319,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 34.3643 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.3148 | |
| Revenue Enterprise Value | 4.3075 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 53,225,500 | |
| Shares Float | 53,036,013 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 0.41 | |
| Institutions (%) | 105.76 | |
06/30 16:27 EST - globenewswire.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC (“LivaNova” or the “Company”) (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of LivaNova PLC - LIVN
NEW YORK, June 30, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of LivaNova PLC (“LivaNova” or the “Company”) (NASDAQ: LIVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
06/24 18:24 EST - businesswire.com
Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach.
Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach
OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates LivaNova USA, Inc. for Data Breach.
06/18 09:00 EST - businesswire.com
LivaNova to Announce Second-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To list.
LivaNova to Announce Second-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2024 results on Wednesday, July 31, 2024 at 1 p.m. London time (8 a.m. Eastern Time). The Company will release its second-quarter 2024 results prior to the call. A live audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To list.
06/06 09:00 EST - businesswire.com
LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced preliminary results for the unipolar cohort of the RECOVER study, assessing use of VNS Therapy in treatment-resistant depression.
LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced preliminary results for the unipolar cohort of the RECOVER study, assessing use of VNS Therapy in treatment-resistant depression.
05/23 09:00 EST - businesswire.com
LivaNova to Present at the Goldman Sachs Healthcare Conference
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova announced Vladimir Makatsaria, CEO, will present a fireside chat at the Goldman Sachs Conference in Miami, Florida at 1:20 pm ET on June 10.
LivaNova to Present at the Goldman Sachs Healthcare Conference
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova announced Vladimir Makatsaria, CEO, will present a fireside chat at the Goldman Sachs Conference in Miami, Florida at 1:20 pm ET on June 10.
05/01 08:10 EST - zacks.com
LivaNova (LIVN) Q1 Earnings and Revenues Top Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43 per share a year ago.
LivaNova (LIVN) Q1 Earnings and Revenues Top Estimates
LivaNova (LIVN) came out with quarterly earnings of $0.73 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.43 per share a year ago.
05/01 06:00 EST - businesswire.com
LivaNova Reports First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.
LivaNova Reports First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC reported results for the quarter ended March 31, 2024 and raised full-year 2024 revenue and adjusted diluted earnings per share guidance.
04/30 09:00 EST - businesswire.com
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer, effective May 13, 2024.
LivaNova Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Ahmet Tezel, Ph.D., will join the Company as Chief Innovation Officer, effective May 13, 2024.
04/25 16:03 EST - businesswire.com
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova's wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident in late 2023.
LivaNova Issues Notice to U.S. Patients Regarding Cybersecurity Incident
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova's wholly-owned U.S. subsidiary, LivaNova USA, Inc., is providing notice to U.S. patients regarding a cybersecurity incident in late 2023.
04/24 11:06 EST - zacks.com
LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
LivaNova (LIVN) Earnings Expected to Grow: Should You Buy?
LivaNova (LIVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
03/21 09:00 EST - businesswire.com
LivaNova to Announce First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova will host a conference call to discuss its first-quarter 2024 results on Wed, May 1, 2024 at 1 p.m. London time (8 a.m. ET).
LivaNova to Announce First-Quarter 2024 Results
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova will host a conference call to discuss its first-quarter 2024 results on Wed, May 1, 2024 at 1 p.m. London time (8 a.m. ET).
03/21 05:51 EST - zacks.com
LivaNova (LIVN) Soars 12.5%: Is Further Upside Left in the Stock?
LivaNova (LIVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
LivaNova (LIVN) Soars 12.5%: Is Further Upside Left in the Stock?
LivaNova (LIVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
03/20 09:00 EST - businesswire.com
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its OSPREY clinical study has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated.
LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its OSPREY clinical study has achieved a positive predictive outcome and will conclude enrollment earlier than anticipated.
03/05 21:55 EST - businesswire.com
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 issued in a private offering.
LivaNova Announces Pricing of Private Offering of $300 Million of 2.50% Convertible Senior Notes Due 2029
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova announced the pricing of $300 million aggregate principal amount of 2.50% convertible senior notes due 2029 issued in a private offering.
03/04 16:44 EST - businesswire.com
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 in a private offering.
LivaNova Announces Proposed Private Offering of $300 Million of Convertible Senior Notes
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced its intention to offer $300 million aggregate principal amount of convertible senior notes due 2029 in a private offering.
03/04 09:00 EST - businesswire.com
LivaNova to Present at the Barclays Global Healthcare Conference
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova announced Vladimir Makatsaria, CEO, will present in a fireside chat at the Barclays Conference in Miami, Florida at 10:45 am ET on March 12.
LivaNova to Present at the Barclays Global Healthcare Conference
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova announced Vladimir Makatsaria, CEO, will present in a fireside chat at the Barclays Conference in Miami, Florida at 10:45 am ET on March 12.